<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950339</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-09-SB-0196-09-TLV-CTIL</org_study_id>
    <nct_id>NCT00950339</nct_id>
  </id_info>
  <brief_title>Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine</brief_title>
  <official_title>Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tel Aviv Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current guidelines recommend the addition of proton pump inhibitors (PPI) to patients taking&#xD;
      double anti-platelet therapy (Aspirin and Clopidogrel) to prevent upper GI bleeding1. Many&#xD;
      post percutaneous coronary intervention (PCI) patients are treated with dual anti-platelet&#xD;
      medications as well as PPI to prevent upper GI bleeding.&#xD;
&#xD;
      Recently, it was shown that PPI interact with the P450 system in the liver and reduce the&#xD;
      platelet inhibitory effect of Clopidogrel2,3. Clopidogrel is activated by CYP2C19, which also&#xD;
      metabolizes PPI4. Furthermore, a recent article showed increased mortality in patients taking&#xD;
      PPI and clopidogrel compared with patients taking clopidogrel without PPI protection5. The&#xD;
      degree of reduction in the platelet inhibitory properties of clopidogrel might vary among the&#xD;
      different PPI4.&#xD;
&#xD;
      The use of PPI for GI protection in patients treated with dual anti-platelet therapy is not&#xD;
      based on randomized trials, but rather on expert opinion. Since H2 blockers are also&#xD;
      effective in preventing acid secretion and are not known to interact with the P450 system&#xD;
      that affects clopidogrel, the investigators hypothesized that these group of drugs will not&#xD;
      interfere with the positive antiplatelet effects of clopidogrel and therefore will offer a&#xD;
      good alternative treatment option.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study we will compare 3 different anti-acids regimens and their effect on platelet&#xD;
      function&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet function as assessed by a CPA system</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Coronary Heart Disease</condition>
  <condition>GI Bleeding</condition>
  <arm_group>
    <arm_group_label>4 weeks of omeprazole, 20mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will undergo 3 phases of drug therapy:&#xD;
A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).&#xD;
At the end of each phase- each patient will undergo the following evaluation:&#xD;
Platelet reactivity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 weeks of famotidine 40mg twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will undergo 3 phases of drug therapy:&#xD;
A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).&#xD;
At the end of each phase- each patient will undergo the following evaluation:&#xD;
Platelet reactivity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 weeks of pantoprazole 40mg once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each patient will undergo 3 phases of drug therapy:&#xD;
A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).&#xD;
At the end of each phase- each patient will undergo the following evaluation:&#xD;
Platelet reactivity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole, 20mg twice daily</intervention_name>
    <description>Each patient will undergo 3 phases of drug therapy:&#xD;
A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).&#xD;
At the end of each phase- each patient will undergo the following evaluation:&#xD;
Platelet reactivity</description>
    <arm_group_label>4 weeks of famotidine 40mg twice daily</arm_group_label>
    <arm_group_label>4 weeks of omeprazole, 20mg twice daily</arm_group_label>
    <arm_group_label>4 weeks of pantoprazole 40mg once daily</arm_group_label>
    <other_name>PPI Platelet Inhibitory</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>famotidine 40mg twice daily</intervention_name>
    <description>Each patient will undergo 3 phases of drug therapy:&#xD;
A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).&#xD;
At the end of each phase- each patient will undergo the following evaluation:&#xD;
Platelet reactivity</description>
    <arm_group_label>4 weeks of famotidine 40mg twice daily</arm_group_label>
    <arm_group_label>4 weeks of omeprazole, 20mg twice daily</arm_group_label>
    <arm_group_label>4 weeks of pantoprazole 40mg once daily</arm_group_label>
    <other_name>PPI Platelet Inhibitory</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pantoprazole 40mg once daily</intervention_name>
    <description>Each patient will undergo 3 phases of drug therapy:&#xD;
A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).&#xD;
At the end of each phase- each patient will undergo the following evaluation:&#xD;
Platelet reactivity</description>
    <arm_group_label>4 weeks of famotidine 40mg twice daily</arm_group_label>
    <arm_group_label>4 weeks of omeprazole, 20mg twice daily</arm_group_label>
    <arm_group_label>4 weeks of pantoprazole 40mg once daily</arm_group_label>
    <other_name>PPI Platelet Inhibitory</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is at least 18 years old.&#xD;
&#xD;
          2. Subject is willing to comply with pre-specified follow-up evaluation and can be&#xD;
             contacted by telephone.&#xD;
&#xD;
          3. Use of Clopidogrel (&gt;=75mg) and Aspirin(&gt;=75mg) for at least 1 month.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy to PPI of H2 blockers&#xD;
&#xD;
          2. Known thrombocytopenia or thrombocytopathia&#xD;
&#xD;
          3. Subject is currently enrolled in another investigational study of a new drug, biologic&#xD;
             or device at the time of study screening. NOTE: Subjects who are participating in the&#xD;
             long term follow-up phase of a previously investigational and now FDA-approved product&#xD;
             are not excluded by this criterion.&#xD;
&#xD;
          4. Subject with symptomatic heart failure of LVEF â‰¤ 25%&#xD;
&#xD;
          5. Acute myocardial infarction within the past 30 days.&#xD;
&#xD;
          6. No acute inflammatory event during the past month (e.g. infection, autoimmune or acute&#xD;
             coronary event)&#xD;
&#xD;
          7. Concurrent medical condition with a life expectancy of less than 12 months.&#xD;
&#xD;
          8. Known severe renal failure (serum creatinine level &gt;2.5 mg/dl).&#xD;
&#xD;
          9. History of bleeding diathesis or coagulopathy or inability or unwillingness to receive&#xD;
             blood transfusions.&#xD;
&#xD;
         10. Evidence of active gastrointestinal bleeding or a history of such bleeding that is not&#xD;
             known to have been treated and proven to have resolved.&#xD;
&#xD;
         11. History of hepatitis (viral, ischemic or chemically-induced); clinical jaundice,&#xD;
             history of cirrhosis.&#xD;
&#xD;
         12. Patient treated with anticoagulant medication (Coumadin, LMWH)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shmuel Banai, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tel Aviv Medical Center, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>April 19, 2009</study_first_submitted>
  <study_first_submitted_qc>July 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2009</study_first_posted>
  <last_update_submitted>July 6, 2016</last_update_submitted>
  <last_update_submitted_qc>July 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tel-Aviv Sourasky Medical Center</investigator_affiliation>
    <investigator_full_name>michal roll</investigator_full_name>
    <investigator_title>Interventional cardiologist</investigator_title>
  </responsible_party>
  <keyword>GI bleeding</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>aspirin</keyword>
  <keyword>prevention</keyword>
  <keyword>angiography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

